[Targeted Therapies with BRAF Inhibitors for Pediatric Low- and High-Grade Gliomas with BRAFv600e Mutation. Prof. Dr. Juan P. Garrahan Hospital Experience].

Targeted therapies with BRAF inhibitors for pediatric low-and high-grade gliomas with BRAF(v600e) mutation. Prof. Dr. Juan P. Garrahan Hospital experience. The BRAF(V600E) point mutation plays a key role in the tumorigenesis of many gliomas. Inhibiting its product is part of the innovative therapies emerging in recent years. Knowing the role of these treatments is essential. The aim of this experience was to describe the clinical-radiological response of pediatric BRAF(V600E) mutated gliomas treated with BRAF inhibitors. To this end, a descriptive and retrospective study was performed in patients under 16 years of age with BRAF(V600E) gliomas, who received vemurafenib or dabrafenib at Hospital Garrahan. Thirteen patients treated in the last 7 years were included: 9 were low-grade and 4 high-grade gliomas. The median age at diagnosis was 8.6 years (0.89-14.04) and at start of targeted therapy was 11.62 years (3.64-15.42). All patients had previously a surgical procedure, and 12/13 had received another therapy prior BRAF inhibition: 11 chemotherapy (in one case, up to 4 different protocols) and 4 radiotherapy. Under targeted therapy, tumour response was obtained in 10 patients (size reduction equal to or greater than 25%), and best response was observed in the first 6 months of treatment in 7 children. Four patients progressed under treatment (all high-grade gliomas) and 2 progressed shortly after stopping the inhibitor (both low-grade gliomas). Five patients had grade 3-4 toxicity, with subsequent full recovery. A good and sustained clinical-radiological response, with acceptable tolerance, is described in patients with BRAF(V600E) mutated low-grade gliomas treated with BRAF(V600E) inhibitors. In contrast, the response in patients with high-grade gliomas was intermediate and of short duration, with early tumour progression.